- Going concern
- No material uncertainty
- Principal risks
- 5
| 6 Mar 2024 | Annual Report and Accounts (to 2023-08-31) | |
| 31 Mar 2023 | Annual Report and Accounts (to 2022-08-31) | |
| 13 Dec 2021 | Annual Report and Accounts (to 2021-05-31) |
Oncimmune is a prominent developer of immunodiagnostics, with a primary focus on the expanding areas of immuno-oncology, autoimmune disorders, and infectious diseases.
| 6 Mar 2024 | Annual Report and Accounts (to 2023-08-31) | |
| 31 Mar 2023 | Annual Report and Accounts (to 2022-08-31) | |
| 13 Dec 2021 | Annual Report and Accounts (to 2021-05-31) |
Oncimmune is a prominent developer of immunodiagnostics, with a primary focus on the expanding areas of immuno-oncology, autoimmune disorders, and infectious diseases.